PubMed · 2016 · 21 citations · 18 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyInterventional CardiologyAcute Coronary Syndrome InterventionAcute Coronary SyndromesAntiplatelet TherapyAntithrombotic TherapyCoronary Artery DiseaseThrombosisAcute Coronary Syndrome ManagementAntiplatelet DrugsAntiplatelet Therapy After Percutaneous Coronary InterventionCombination Antiplatelet TherapyCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2c19-guided Antiplatelet TherapyPercutaneous Coronary Intervention Care
Objective The present study was designed to compare the outcome and safety of dual antiplatelet therapies (DAPTs) in patients with acute coronary syndrome (ACS) (intermediate metabolizers [IM] or poor metabolizers [PM]) undergoing percutaneous coronary intervention (PCI).Methods and results From September 20, 2013, to June 8, 2014, the study enrolled 329 patients with ACS scheduled for PCI. Of these, 181 (55%) patients with IM or PM were randomized in a 1:1 ratio to receive either high-dose clopidogrel or ticagrelor. The high-dose clopidogrel group received a 600-mg loading dose (LD) and finally 75 mg QD, and the ticagrelor group received 180 mg LD following 90 mg b.i.d. After 6 months of DAPT, the primary end point (composition of death, stroke, recurrent myocardial infarction [MI], and stent thrombosis) occurred in 4.4% of patients receiving ticagrelor compared with 20.0% of those receiving high-dose clopidogrel (P <0.001). Survival probability analysis revealed a higher survival rate with ticagrelor (9...
18